Neurogene (NGNE) Liabilities and Shareholders Equity (2013 - 2026)

Neurogene has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $263.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 16.54% year-over-year to $263.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 14.26% YoY), and the FY2025 full-year result was $288.6 million, down 14.04% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $263.1 million, down from $288.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $335.7 million in Q4 2024, with the low at $89.6 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $197.3 million across 5 years, with a median of $179.8 million in 2024.
• The largest YoY upside for Liabilities and Shareholders Equity was 103.7% in 2023 against a maximum downside of 33.98% in 2023.
• Neurogene's Liabilities and Shareholders Equity stood at $109.3 million in 2022, then jumped by 103.7% to $222.6 million in 2023, then soared by 50.84% to $335.7 million in 2024, then slipped by 14.04% to $288.6 million in 2025, then dropped by 8.82% to $263.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $263.1 million (Q1 2026), $288.6 million (Q4 2025), and $287.8 million (Q3 2025), per Business Quant data.